Clinical Research Directory

Inclusion Criteria: * Subjects eligible for inclusion in this study must meet all of the following criteria: 1. Patients with malignant hematological diseases undergo haploid/sibling incomplete matching/unrelated donor transplantation; 2. Recurrence after transplantation (morphological, extramedullary, or molecular recurrence); 3. Plan to administer granulocyte colony-stimulating factor mobilization donor lymphocyte infusion (gDLI) for treatment; 4. No age, gender, or race restrictions; 5. The physical condition assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points; 6. The patient or their authorized representative agrees to participate in the clinical trial and signs an informed consent form. Exclusion Criteria: * Subjects meeting any of the following criteria are not eligible for inclusion in this study: 1. Siblings of matched donor transplant; 2. Patients with other malignant tumors that require treatment; 3. There are active infections, such as hepatitis B, hepatitis C, tuberculosis, etc; 4. HIV serological reaction was positive; 5. Suffering from mental illness or other conditions that cannot comply with research, treatment, and monitoring requirements; 6. Pregnant patients or patients who are unable to take appropriate contraceptive measures during treatment; 7. Active heart disease is defined as one or more of the following: 1. Have a history of uncontrolled or symptomatic angina pectoris; 2. Myocardial infarction less than 6 months prior to enrollment in the study; 3. A history of arrhythmia requiring medication treatment or severe clinical symptoms; 4. Uncontrolled or symptomatic congestive heart failure (\>NYHA level 2); 5. The ejection fraction is below the lower limit of the normal range. 8. Individuals who are allergic to any medication or component such as Cy, CNI, etc; 9. The researchers believe that it is not suitable for participants.